title: Optimized protocol for quantification of extracellular nicotinamide adenine dinucleotide: evaluating clinical parameters and pre-analytical factors for translational research
Creators: name: Saqr, Al-Hussein Ahmed
name: Kamali, Can
name: Brunnbauer, Philipp
name: Haep, Nils
name: Koch, Pia
name: Hillebrandt, Karl-Herbert
name: Keshi, Eriselda
name: Moosburner, Simon
name: Mohr, Raphael
name: Raschzok, Nathanael
name: Pratschke, Johann
name: Krenzien, Felix
Publisher: name: Charité - Universitätsmedizin Berlin
Year: 2024
Subjects: subject: extracellular
subject: nicotinamide adenine dinucleotide (NAD(+))
subject: quantification
subject: plasma
subject: enzymatic assay
subject: intracellular
subject: clinical parameters
subject: pre-analytical factors
classificationCode: 610
subject: Medizin und Gesundheit

description: Nicotinamide adenine dinucleotide (NAD(+)), a coenzyme for more than 500 enzymes, plays a central role in energy production, metabolism, cellular signaling, and DNA repair. Until recently, NAD(+) was primarily considered to be an intracellular molecule (iNAD(+)), however, its extracellular species (eNAD(+)) has recently been discovered and has since been associated with a multitude of pathological conditions. Therefore, accurate quantification of eNAD(+) in bodily fluids such as plasma is paramount to answer important research questions. In order to create a clinically meaningful and reliable quantitation method, we analyzed the relationship of cell lysis, routine clinical laboratory parameters, blood collection techniques, and pre-analytical processing steps with measured plasma eNAD(+) concentrations. Initially, NAD(+) levels were assessed both intracellularly and extracellularly. Intriguingly, the concentration of eNAD(+) in plasma was found to be approximately 500 times lower than iNAD(+) in peripheral blood mononuclear cells (0.253 +/- 0.02 mu M vs. 131.8 +/- 27.4 mu M, p = 0.007, respectively). This stark contrast suggests that cellular damage or cell lysis could potentially affect the levels of eNAD(+) in plasma. However, systemic lactate dehydrogenase in patient plasma, a marker of cell damage, did not significantly correlate with eNAD(+) (n = 33; r = -0.397; p = 0.102). Furthermore, eNAD(+) was negatively correlated with increasing c-reactive protein (CRP, n = 33; r = -0.451; p = 0.020), while eNAD(+) was positively correlated with increasing hemoglobin (n = 33; r = 0.482; p = 0.005). Next, variations in blood drawing, sample handling and pre-analytical processes were examined. Sample storage durations at 4 degrees C (0-120 min), temperature (0 degrees to 25 degrees C), cannula sizes for blood collection and tourniquet times (0 - 120 s) had no statistically significant effect on eNAD(+) (p &gt; 0.05). On the other hand, prolonged centrifugation (&gt; 5 min) and a faster braking mode of the centrifuge rotor (&lt; 4 min) resulted in a significant decrease in eNAD(+) levels (p &lt; 0.05). Taken together, CRP and hemoglobin appeared to be mildly correlated with eNAD(+) levels whereas cell damage was not correlated significantly to eNAD(+) levels. The blood drawing trial did not show any influence on eNAD(+), in contrast, the preanalytical steps need to be standardized for accurate eNAD(+) measurement. This work paves the way towards robust eNAD(+) measurements, for use in future clinical and translational research, and provides an optimized hands-on protocol for reliable eNAD(+) quantification in plasma.